Turbo, Antioquia, Colombia January 8, 2018
GMS (Inca Worldwide’s partner) received the INVIMA licenses for the following Sacha Inchi products and names:
Semilla de la Paz
Harina de Sacha Inchi
Harina el Indio
Semilla de la Paz
Snacks Sacha Inchi
The INVIMA license process follows the same regulatory protocol as the U.S.’s FDA. The licenses will allow us to export to and sell in the USA. We will also begin evaluation search for a medical team to test our products under GCP. GCP is the Good Clinical Practice, an international ethical and scientific quality standard which provides a unified standard for the United States, the European Union, and Japan to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions. Approval will make our Sacha Inchi powder and snacks the first to be tested and approved under FDA regulation as a real Super Food.
Contact information: email@example.com
About Inca Worldwide
Our Inca Seeds (Roasted Sacha Inchi) contain a complete protein with all nine essential amino acids, and they are rich in Omega 3, 6, and 9 antioxidants—a real Superfood!
Caution Concerning Forward-Looking Statements:
Our public communications and SEC filings may contain "forward-looking statements" – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," or "target."
Forward-looking statements by their nature address matters that are, to various degrees, uncertain, such as statements about our announced plan to reduce the size of our financial-services businesses, including expected cash and non-cash charges associated with this plan and earnings per share of QED retained businesses (Verticals); expected income; earnings per share; revenues; organic growth; growth and productivity associated with our Digital business; margins; cost structure; restructuring charges; acquisition-related synergies; cash flows; returns on capital and investment; capital expenditures, capital allocation or capital structure; and dividends.